文献速递临床试验与 GCP基础与转化研究

中药协同模式联合辅助化疗对IIIb和IIIc期胃癌的影响:随机对照试验方案

Effects of traditional Chinese medicine collaborative model (TCMCM) combined with adjuvant chemotherapy on IIIb and IIIc gastric cancer: a protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-01-21

该前瞻性、多中心、随机、开放标签试验拟纳入260例接受根治性手术及D2淋巴结清扫的IIIb和IIIc期胃癌患者,按1:1随机分为中药协同模式(TCMCM)联合辅助化疗组与单纯辅助化疗组。主要结局为3年无病生存率,次要结局包括生活质量、化疗副作用及安全性指标,并收集生物样本进行机制分析。

要点

  • TCMCM联合辅助化疗组接受口服中药方剂、耳穴贴压和穴位疗法。
  • 主要结局为3年无病生存率,评估时间点为辅助化疗第4、8周期及随机后9至36个月。
  • 试验注册号NCT03607656,注册日期2018年7月1日,方案版本V1.1。

核心结论

  • 这是首个评估TCMCM对IIIb和IIIc期胃癌患者无病生存率和生活质量影响的临床试验。
  • 研究结果可能用于标准化TCMCM,未来将开展更大规模临床试验。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签试验,拟招募260例接受根治性手术及D2淋巴结清扫的IIIb和IIIc期胃癌患者。
  • 患者按1:1随机分配接受常规辅助化疗联合TCMCM(干预组)或单纯常规辅助化疗。
  • 干预组接受口服中药方剂、耳穴贴压和穴位疗法;所有参与者均接受常规辅助化疗。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 主要结局为3年无病生存率。
  • 次要结局包括生活质量、化疗引起的副作用及安全性相关指标。
  • 评估在筛选期、辅助化疗第4和第8周期后、随机后9、12、18、24、30和36个月进行。
  • 不良事件将被记录,并收集生物样本用于机制分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastasis and/or recurrence can decrease the survival time of gastric cancer patients undergoing radical operation. Among them, those with stage IIIb and IIIc are especially at a high risk of metastasis and recurrence. The traditional Chinese medicine collaborative model (TCMCM) has been used in the treatment of cancer; however, its effects have not been systematically evaluated. This study is designed to evaluate whether TCMCM can decrease adverse effects after chemotherapy and reduce the recurrence and metastasis of stage IIIb and IIIc gastric cancer. METHODS/DESIGN: This prospective, multicenter, randomized, open-label trial will recruit 260 patients with stage IIIb and IIIc gastric cancer who undergo radical surgery for D2 lymphadenectomy. The patients will be randomly assigned to receive usual adjuvant chemotherapy and TCMCM (intervention group) in a 1:1 ratio. Patients in the intervention group will receive an oral traditional Chinese formula, auricular acupressure, and acupoint therapy. All participants will receive usual adjuvant chemotherapy. The primary outcome is a 3-year disease-free survival rate. Secondary outcomes include quality of life, side effects caused by chemotherapy, and safety-related measures. Assessments will be performed during the screening period, at 4 and 8 cycles after adjuvant chemotherapy, and 9, 12, 18, 24, 30, and 36 months after randomization. Adverse events will be recorded. In addition, biological samples will be collected for mechanism analysis. DISCUSSION: This will be the first clinical trial to evaluate the effects of TCMCM on disease-free survival (DFS) and quality of life in patients with stage IIIb and IIIc gastric cancer. Our results may be used to standardize TCMCM. We will also perform a larger-scale clinical trial in the future. TRIAL REGISTRATION: ClinicalTrials.gov NCT03607656 . Registered on 1 July 2018. The final protocol version is V1.1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li Z, Zhang G, Cao N, et al. Effects of traditional Chinese medicine collaborative model (TCMCM) combined with adjuvant chemotherapy on IIIb and IIIc gastric cancer: a protocol for a randomized controlled trial. Trials. 2022. PMID: 35063002. doi:10.1186/s13063-022-06013-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。